DSM's cGMP biologics plant a boon to Australian biotech, firm says
DSM says its new biomanufacturing facility will benefit the Australian biotech sector, overcoming the problems of distance with foreign contract manufacturers.
Archives for October 30, 2013
update
Stada to sell Apotex' biosimilar filgrastim in Europe
Stada Arzneimittel has licensed European rights to a biosimilar version of the white blood cell booster filgrastim from Apotex and says it is not worried by competitors already in the market.
Dispatches from CPhI
'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI
Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.
Cobra Biologics moves to beef up mAb capacity
Corba Biologics has opted for a HyClone bioreactor to boost its antibody production capacity citing customer demand and biosimilars as the drivers for the investment.